Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C

Hepatology

Volumn 46, Issue 2, 2007, Pages 315-323

  Chan, Henry L Y ^a,e   Ren, Hong ^b   Chow, Wan C ^c   Wee, Theodore ^d  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d Serono Singapore Ltd   (Singapore)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; PLACEBO; RIBAVIRIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; ASIAN; ASTHENIA; BACKACHE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; GRANULOCYTOPENIA; HEADACHE; HEART PALPITATION; HEPATITIS C; HUMAN; HUMAN TISSUE; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; LIVER BIOPSY; MALAISE; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RIGOR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 34548314078     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21683     Document Type: Article

References (30)

1. Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002;136:747-757.
2. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
3. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
4. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225-230.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
8. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-15628.
9. Colamonici OR, Pfeffer LM. Structure of the human interferon alpha receptor. Pharmacol Ther 1991;52:227-233.
10. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 1989;9:4605-4612.
11. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. J Biol Chem 1994;269:17761-17764.
12. Gold R, Rieckmann P, Chang P, Abdalla J; Prisms Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005;12:649-656.
13. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, et al. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000;45:2414-2421.
14. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, et al. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 2000;20:437-441.
15. Kaito M, Yasui-Kawamura N, Iwasa M, Kobayashi Y, Nakagawa N, Fujita N, et al. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology 2003;50:775-778.
16. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. HEPATOLOGY 2001;34:377-384.
17. Castro A, Suarez D, Inglada L, Carballo E, Dominguez A, Diago M, et al. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 1997;17:27-30.
18. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001;36:242-247.
19. Kakizaki S, Takagi H, Yamada T, Ichikawa T, Abe T, Sohara N, et al. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. J Viral Hepat 1999;6:315-319.
20. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, et al. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol 1999;34:928-933.
21. Cheng PN, Marcellin P, Bacon B, Farrell G, Parsons I, Wee T, et al. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat 2004;11:418-426.
22. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
23. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
24. Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
25. Brandao C, Barone A, Carrilho F, Silva A, Parelli M, Caramori C, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat 2006;13:552-559.
26. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006;40:74-82.
27. Pellicano R, Craxi A, Almasio PL, Valenza M, Venezia G, Alberti A, et al. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005;11:4484-4489.
28. Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004;10:12-16.
29. Moreno-Otero R, Trapero-Marugan M, Gomez-Dominguez E, Garcia-Buey L, Moreno-Monteagudo JA. Is interferon-beta an alternative treatment for chronic hepatitis C? World J Gastroenterol 2006;12:2730-2736.
30. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-1359.